Article Text


Viral hepatitis
P71 Antiviral treatment of recurrent hepatitis C after liver transplantation—the Newcastle experience
  1. S McPherson,
  2. M Hudson,
  3. D Sheridan,
  4. C Miller,
  5. K Baxter,
  6. M Bassendine
  1. Hepatology Department, Freeman Hospital, Newcastle-upon-Tyne, UK


Introduction Recurrence of hepatitis C (HCV) post liver transplantation is universal and may follow a rapidly progressive course, which results in poorer long-term graft survival rates compared with other liver diseases. Sustained virological response (SVR) after anti-viral treatment has recently been shown to significantly improve liver histology and long-term survival1.

Aim To describe our experience of the treatment of recurrent HCV post liver transplantation.

Method Retrospective case-note review of all patients transplanted for HCV.

Results 41 patients were transplanted in Newcastle for chronic HCV (10 had HCC) between 1993 and 2008. Up to 2002 our 5 year survival for patients with HCV was 45%. In order to try and improve this antiviral therapy was offered to patients from 2002. 15 patients (median age 50, range 38–68; 11 (73%) male) received individualised treatment with pegylated interferon (PEG-IFN) +/- ribavirin (RBV). All had liver biopsy showing recurrent HCV, 3 had cirrhosis and 1 had cholestatic hepatitis. 10 (66%) patients were infected with HCV genotype 1 (G1) and 5 with genotype 3 (G3). 4 patients (27%) achieved SVR following treatment (4 G3 and 1 G1) and 1 patient is currently on treatment and was HCV RNA negative at 12 weeks (G3). All patients who achieved SVR had =48 weeks treatment with PEG-IFN+RBV and had mild hepatic fibrosis. Of the four patients who had an SVR, 2 were taking ciclosporin and 2 tacrolimus. Adverse events were common and led to cessation of therapy in 6 patients (3 pancytopaenia, 1 refractory anaemia, 1 myocardial infarction, 1 hepatic decompensation). All cirrhotic patients stopped treatment due to adverse events. Severe anaemia was very common and 5 patients were treated with erythropoietin (2 had SVR).

Conclusion Treatment of recurrent HCV post-liver transplantation can be successful in selected patients, particularly patients with HCV G3 with mild hepatic fibrosis. This experience has led us to discuss anti-viral therapy at 6 months post liver transplant.

Statistics from

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.